Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Guimaraes – page 57

686 clinical trials in Guimaraes, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Guimaraes at a glance
686
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

686 trials in Guimaraes

Open in trial search

Plasma cell myeloma refractory

Not recruiting

Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Isatuximab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Renal cell carcinoma

Not recruiting

Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Aveo Pharmaceuticals Inc.

Frontotemporal dementia

Not recruiting

Study on the Effects of Latozinemab for Patients with Frontotemporal Dementia Due to Progranulin Gene Mutations

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Latozinemab
  • Sponsor:Alector LLC

Hormone-refractory prostate cancer+1

Not recruiting

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Squamous cell carcinoma of head and neck

Not recruiting

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Retifanlimab
  • Sponsor:Incyte Biosciences International S.a.r.l.

Dermatitis atopic

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Dupilumab for Children Aged 2 to 12 with Moderate to Severe Atopic Dermatitis

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Dupilumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Volrustomig with a Drug Combination for Patients with Solid Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Bladder transitional cell carcinoma

Not recruiting

Study comparing enfortumab vedotin versus chemotherapy combination (docetaxel, paclitaxel, vinflunine) in patients with previously treated advanced or metastatic bladder cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Astellas Pharma Global Development Inc.

Alveolar proteinosis

Not recruiting

Study of Inhaled Molgramostim for Adults with Autoimmune Pulmonary Alveolar Proteinosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Molgramostim
  • Sponsor:Savara ApS

Primary amyloidosis

Not recruiting

Study on Birtamimab and Bortezomib for Patients with Advanced Light Chain Amyloidosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Birtamimab
  • Sponsor:Prothena Biosciences Limited

Diabetic retinal oedema

Not recruiting

Study on EYE103 and Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Guimaraes

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on TTR amyloidosis cardiomyopathy and treatments for hypertrophic cardiomyopathy. Research includes evaluations of new therapies for stroke prevention in patients with atrial fibrillation.

  • Heart Disease Management
  • Stroke Prevention
  • Cardiovascular Risk Reduction

Multiple trials examining breakthrough treatments for various forms of heart disease and their complications.

02 Respiratory Medicine

Clinical investigations into chronic rhinosinusitis treatments, both with and without nasal polyps. Studies evaluating new therapeutic approaches for respiratory conditions.

  • Nasal Polyp Treatment
  • Rhinosinusitis Management
  • Community-Acquired Pneumonia

Comprehensive research aimed at improving respiratory health outcomes and patient quality of life.

03 Neurological Disorders

Advanced research into multiple sclerosis and Alzheimer's disease related conditions. Studies focus on innovative treatments for both disease management and symptom control.

  • MS Treatment Development
  • Alzheimer's Psychosis
  • Epilepsy Management

Cutting-edge trials exploring new therapeutic options for various neurological conditions.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.